Sugammadex or Neostigmine: Two Patients the Guideline Doesn't Answer the Same Way
One patient's kidneys can't clear the sugammadex-rocuronium complex. The next patient's kidneys are fine, but she's on a hormonal IUD sugammadex is labeled to interact with. Same drug choice, two unrelated reasons it might be wrong.
M.R., a 61-year-old man with stage 4 chronic kidney disease (eGFR 22, not yet on dialysis), is at the end of a four-hour exploratory laparotomy for a perforated diverticulum — longer and deeper than planned once the surgeon found more contamination than the CT suggested. His train-of-four count is zero with post-tetanic count of one, a deep block he needed for the abdominal closure and hasn't yet had a chance to spontaneously recover from.
Deep block at TOF-0/PTC-1 sits below the threshold neostigmine can reliably reverse at all, regardless of renal function — acetylcholinesterase inhibition simply can't outcompete that much residual rocuronium at the neuromuscular junction. Sugammadex reverses deep block by direct encapsulation instead, independent of block depth, but the sugammadex-rocuronium complex is cleared almost entirely renally, and at his eGFR of 22 that clearance will run far slower than in a patient with normal kidneys — and his CrCl of 24 mL/min sits below the line at which the drug's own labeling stops recommending it at all: sugammadex is not recommended in severe renal impairment, defined as CrCl under 30 mL/min, a restriction the FDA label states outright rather than a silence in the literature. Panhuizen and colleagues studied 4 mg/kg reversal in exactly this population and found it did reverse deep block without recurarization — at roughly five-fold higher exposure, with the terminal half-life stretching from about two hours to nineteen and the sugammadex–rocuronium complex still detectable in plasma a week later. He is outside the population the label endorses and inside the small one that has actually been studied, which are not the same thing.
He is not yet on a dialysis schedule, which matters to the discussion in a way it wouldn't if he were: an established hemodialysis patient has a known, predictable route to eventually clear the complex, while M.R.'s own renal trajectory over the coming week is still an open clinical question the surgical team is actively trying to answer, contamination control and further imaging pending. His wife, present for the family update after the case, asks directly whether "the reversal drug" could be part of why his kidneys haven't been recovering the way the surgical team hoped — a fair question the team has no clean answer to yet, since disentangling sugammadex's slower clearance from his underlying CKD trajectory and the physiologic insult of peritonitis itself isn't something a single case can resolve.
I'd favor neostigmine here if his block were shallow enough to reverse with it. This isn't me being conservative about an under-studied drug — the label affirmatively does not recommend sugammadex under a CrCl of 30, and he's at 24. That's a stated restriction I'd rather work around than argue past, in a patient who is about to be my ICU admission for a week.
That's exactly the problem — his block is TOF-0, PTC-1. Neostigmine cannot reliably reverse block that deep in anyone, regardless of kidney function; it's not a dosing question, it's a mechanistic ceiling. The renal-accumulation concern only becomes relevant once sugammadex is already the only option that reaches him.
Agreed — sugammadex is the only agent that reverses him tonight. Agreed that it's the only agent that reaches him tonight — but I want it said out loud that this is an off-label decision, not a walk through a data gap. The label does not recommend sugammadex below a CrCl of 30 and his is 24. What makes me willing anyway is Panhuizen's severe-impairment cohort: 4 mg/kg reversed deep block with no recurarization, at five-fold exposure and a half-life near nineteen hours. So I'll give the standard 4 mg/kg and document the off-label rationale by name, and the ICU gets a specific instruction rather than a general caution — train-of-four monitoring for recurarization through the first 24 hours, not a single check on arrival.
Agreed: sugammadex 4 mg/kg given, full reversal confirmed by TOF ratio >0.9 within four minutes, extubated uneventfully. Handoff to the ICU explicitly flagged the decision as off-label under the FDA's severe-renal-impairment restriction, with the rationale documented by name and a standing order for train-of-four monitoring through the first 24 hours rather than a single check on arrival.
Priya M., a 29-year-old woman, is recovering from a straightforward laparoscopic appendectomy, her block far shallower than M.R.'s — TOF count of 2, well within range for either reversal agent. She mentions, almost in passing while the team reviews her chart, that she has a hormonal IUD placed eight months ago for endometriosis management, a detail that would have gone unremarked if the resident hadn't specifically been taught to ask.
Sugammadex's manufacturer labeling documents a real, mechanistically explained interaction here: the drug's cyclodextrin ring binds progestin-based hormones with meaningful affinity, the same binding mechanism that lets it encapsulate rocuronium, and that binding can reduce circulating progestin levels enough to compromise contraceptive efficacy for the following cycle. The labeling's own mitigation is explicit — seven days of additional non-hormonal contraception after any sugammadex exposure — but only if she's actually told before she leaves recovery, not discovered later on her own.
She mentions the IUD almost apologetically, the way patients sometimes do with contraception details they've learned to expect won't be relevant to whatever's actually being discussed — and in most anesthetic plans it genuinely wouldn't be. It becomes relevant here only because of a specific, narrow interaction most patients, and plenty of clinicians outside anesthesia and reproductive pharmacology, have never heard of. Her block depth (TOF count of 2, achieved with a modest rocuronium dose for a short laparoscopic case) is the detail that actually opens up a real choice: had her surgery run longer or required deeper relaxation the way M.R.'s did, this conversation would have been foreclosed before it started, the same way his was.
Given her block depth, neostigmine and glycopyrrolate are a genuine option here — unlike our last patient, this isn't a mechanistic ceiling. I'd rather use them and sidestep the progestin-binding interaction entirely than manage a labeled interaction we don't have to.
That's a reasonable choice, but I want to be clear it's a preference, not a requirement — the labeling anticipates this exact interaction and provides a mitigation, seven days of backup contraception, precisely so sugammadex remains usable when its faster, more predictable reversal is preferred.
If her block were deeper the way M.R.'s was, this preference wouldn't survive contact with the mechanistic requirement the way it does here.
Whichever you choose, the actual harm I'd worry about is her leaving here not knowing this interaction exists at all — if sugammadex is used, she needs to hear about the seven-day backup requirement explicitly, in writing, before discharge, not find out about it from a pharmacy insert weeks later.
Agreed: neostigmine and glycopyrrolate given, full reversal confirmed, uneventful recovery. Explicit documentation and verbal counseling given before discharge that had sugammadex been used instead, seven days of backup non-hormonal contraception would have been required — recorded in her chart in case a future anesthetic makes sugammadex the better choice for a deeper block.